ECSP045082A - Formulación granular - Google Patents

Formulación granular

Info

Publication number
ECSP045082A
ECSP045082A EC2004005082A ECSP045082A ECSP045082A EC SP045082 A ECSP045082 A EC SP045082A EC 2004005082 A EC2004005082 A EC 2004005082A EC SP045082 A ECSP045082 A EC SP045082A EC SP045082 A ECSP045082 A EC SP045082A
Authority
EC
Ecuador
Prior art keywords
granular formulation
granular
formulation
granulation
oral
Prior art date
Application number
EC2004005082A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23329547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP045082(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of ECSP045082A publication Critical patent/ECSP045082A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

El presente invento se ocupa de la granulación oral de montelukast sódico.
EC2004005082A 2001-10-26 2004-04-23 Formulación granular ECSP045082A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33954901P 2001-10-26 2001-10-26

Publications (1)

Publication Number Publication Date
ECSP045082A true ECSP045082A (es) 2004-06-28

Family

ID=23329547

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005082A ECSP045082A (es) 2001-10-26 2004-04-23 Formulación granular

Country Status (26)

Country Link
US (2) US20030096840A1 (es)
EP (1) EP1441701B1 (es)
JP (1) JP4420671B2 (es)
KR (1) KR101094084B1 (es)
CN (1) CN100591329C (es)
AT (1) ATE385781T1 (es)
AU (1) AU2002333134B2 (es)
BR (1) BR0213477A (es)
CA (1) CA2463947C (es)
CY (1) CY1107400T1 (es)
DE (1) DE60225040T2 (es)
DK (1) DK1441701T3 (es)
EC (1) ECSP045082A (es)
EG (1) EG24380A (es)
ES (1) ES2298431T3 (es)
HR (1) HRP20040367B1 (es)
HU (1) HUP0401670A3 (es)
IL (1) IL161299A0 (es)
MX (1) MXPA04003856A (es)
MY (1) MY148466A (es)
NO (1) NO20042167L (es)
PE (1) PE20030638A1 (es)
PT (1) PT1441701E (es)
SI (1) SI1441701T1 (es)
WO (1) WO2003035036A1 (es)
ZA (1) ZA200402584B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192660A1 (en) * 2003-03-12 2004-09-30 Mullally John P. Protocol for improving vision
CN101128196B (zh) * 2005-03-16 2013-01-02 Meda制药有限及两合公司 用于治疗呼吸系统疾病的抗胆碱能药和白三烯受体拮抗剂的组合
CN100500149C (zh) * 2005-06-22 2009-06-17 晟德大药厂股份有限公司 白三烯素拮抗剂口服液组成
EP3263117A1 (en) 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
PL1976522T5 (pl) 2005-12-30 2019-12-31 Krka Tovarna Zdravil, D.D., Novo Mesto Kompozycja farmaceutyczna zawierająca montelukast
AU2006337648A1 (en) * 2006-02-09 2007-08-16 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of montelukast sodium
CA2661576A1 (en) 2006-09-26 2008-04-03 Taro Pharmaceuticals North America, Inc. Stabilizing compositions for antibiotics and methods of use
EP2262536A4 (en) * 2008-03-26 2013-07-03 Taro Pharmaceuticals North America Inc STABILIZING LIPID COMPOSITIONS FOR ORAL PHARMACEUTICAL AGENTS
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
ES2756706T3 (es) 2008-05-21 2020-04-27 Ferring Bv Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nocturia
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
WO2009153305A2 (en) * 2008-06-19 2009-12-23 Sandoz Ag Pharmaceutical compositions of montelukast sodium
CA2734847C (en) * 2008-08-18 2016-08-30 Mitsubishi Shoji Foodtech Co., Ltd. Novel excipient for mannitol tableting
KR101790188B1 (ko) 2010-03-29 2017-10-25 훼링 비.브이. 속용성 약학 조성물
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
FR2967066B1 (fr) * 2010-11-04 2013-06-14 Ethypharm Sa Utilisation par voie sublinguale de microgranules non comprimes
CN102085187B (zh) * 2011-01-27 2012-01-11 海南美大制药有限公司 孟鲁司特钠脂质体固体制剂
BR112014001760A2 (pt) 2011-07-26 2017-03-07 Sun Pharma Advanced Res Co Ltd antagonistas de leucotrieno cisteínico
MX345674B (es) 2011-09-16 2017-02-10 Ferring Bv Composicion farmaceutica de disolucion rapida.
WO2013077829A1 (en) 2011-11-21 2013-05-30 Mahmut Bilgic Water-soluble pharmaceutical granules
RU2014152445A (ru) * 2012-07-12 2016-08-27 Ферринг Б.В. Композиции на основе диклофенака
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
US20140072628A1 (en) * 2012-09-12 2014-03-13 Glenmark Generics Ltd. Stable pharmaceutical composition of saxagliptin
CN103520130B (zh) * 2013-10-15 2020-08-04 天垚医药科技发展（上海）有限公司 孟鲁斯特钠择时控释片及其制备方法
CN103520129B (zh) * 2013-10-15 2020-07-31 天垚医药科技发展（上海）有限公司 一种孟鲁斯特钠脉冲释放制剂
CN103520136B (zh) * 2013-10-15 2020-07-31 天垚医药科技发展（上海）有限公司 孟鲁斯特钠脉冲胶囊及其制备方法
CN104644564A (zh) * 2013-11-25 2015-05-27 天津汉瑞药业有限公司 一种含孟鲁司特钠的稳定的颗粒制剂及其制备方法
CN103655497B (zh) * 2013-12-18 2018-05-29 北京华禧联合科技发展有限公司 一种孟鲁司特钠口腔崩解片及其制备方法
JP2017503814A (ja) 2014-01-22 2017-02-02 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 部分的コントロール状態の重症喘息またはコントロール不良状態の重症喘息のｐｄｅ４インヒビターを用いた（およびロイコトリエン調節薬と組み合わせて用いた）治療
CN103720672B (zh) * 2014-01-26 2016-03-16 新疆特丰药业股份有限公司 孟鲁司特钠咀嚼片及其粉末直接压片制备方法
CN104840427B (zh) * 2014-02-13 2017-09-29 长春海悦药业股份有限公司 一种含有孟鲁司特钠的药物组合物
WO2016148455A2 (ko) * 2015-03-13 2016-09-22 경희대학교 산학협력단 몬테루카스트의 생체이용률을 개선시키기 위한 방법
JP6489435B2 (ja) * 2015-04-20 2019-03-27 高田製薬株式会社 モンテルカストナトリウム顆粒製剤
CN107595783A (zh) * 2017-06-01 2018-01-19 合肥远志医药科技开发有限公司 一种孟鲁司特钠颗粒及其制备方法
CN109833302A (zh) * 2017-11-29 2019-06-04 扬子江药业集团有限公司 一种稳定的孟鲁司特钠咀嚼片及其制备方法
CN110787139A (zh) * 2018-08-01 2020-02-14 北京万全德众医药生物技术有限公司 一种孟鲁司特钠药物组合物
CN112789037A (zh) 2018-09-06 2021-05-11 创新药物筛选有限公司 用于治疗哮喘或帕金森病的方法和药物组合物
CN111110679A (zh) * 2018-10-31 2020-05-08 长春海悦药业股份有限公司 一种含有孟鲁司特钠的药物组合物
CN111249238A (zh) * 2020-01-19 2020-06-09 安徽省先锋制药有限公司 一种孟鲁司特钠颗粒制剂方法
US12383547B2 (en) 2020-07-01 2025-08-12 Vanderbilt University Methods of treatment for a kidney disease
US11844792B2 (en) * 2020-07-10 2023-12-19 Sean Downing Treatment for severe acute respiratory illness associated with coronavirus
CN111840233B (zh) * 2020-07-29 2022-05-06 浙江诺得药业有限公司 一种孟鲁司特钠固体分散体、其制备方法及其应用
CN115770222B (zh) * 2021-09-05 2025-09-26 山东新时代药业有限公司 一种孟鲁司特钠颗粒剂及其制备方法
CN114224847B (zh) * 2021-12-07 2023-09-15 哈尔滨珍宝制药有限公司 一种孟鲁司特钠颗粒的制备方法
CN114425040A (zh) * 2022-02-24 2022-05-03 佑华医药科技有限公司 一种孟鲁司特钠颗粒的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561301A (en) * 1976-01-02 1980-02-20 Beecham Group Ltd Orally administrable pharmaceutical composition
CA1338596C (en) 1988-09-27 1996-09-17 Hiroyoshi Koyama Granules having core and their production
FI894611L (fi) 1988-09-30 1990-03-31 May & Baker Ltd Granulaera farmaceutiska preparat.
EP0390435B1 (en) * 1989-03-29 1994-01-05 Takeda Chemical Industries, Ltd. Vitamin B group compound composition and its production
JP2800242B2 (ja) 1989-03-30 1998-09-21 大正製薬株式会社 粒剤の製造方法
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
JP2820829B2 (ja) 1991-03-07 1998-11-05 武田薬品工業株式会社 有核散剤およびその製造方法
JPH0967247A (ja) 1995-08-31 1997-03-11 Taisho Pharmaceut Co Ltd 均一な微粒子製剤の製造方法
JPH11514382A (ja) * 1995-11-02 1999-12-07 メルク フロスト カナダ アンド カンパニー 新規な湿粒法
CA2245162A1 (en) * 1996-02-08 1997-08-14 Merck & Co., Inc. Method of treatment and pharmaceutical composition
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
PL193131B1 (pl) * 1997-12-23 2007-01-31 Schering Corp Kompozycja farmaceutyczna zawierająca kombinację składników aktywnych i jej zastosowanie
US6224907B1 (en) * 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
US6221880B1 (en) * 1998-10-09 2001-04-24 Schering Corporation Composition and method for treating allergic diseases
US6103735A (en) * 1998-10-09 2000-08-15 Schering Corporation Composition and method for treating allergic diseases
AT413647B (de) 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US20030031720A1 (en) 2000-02-24 2003-02-13 Tobias Laich Method for producing pharmaceutical dosage forms
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form

Also Published As

Publication number Publication date
US8007830B2 (en) 2011-08-30
JP2005510497A (ja) 2005-04-21
HUP0401670A2 (hu) 2008-05-28
JP4420671B2 (ja) 2010-02-24
HUP0401670A3 (en) 2008-08-28
CA2463947A1 (en) 2003-05-01
WO2003035036A1 (en) 2003-05-01
CY1107400T1 (el) 2012-12-19
DE60225040D1 (de) 2008-03-27
DK1441701T3 (da) 2008-05-26
MXPA04003856A (es) 2004-07-08
DE60225040T2 (de) 2009-02-26
HRP20040367A2 (xx) 2005-06-30
MY148466A (en) 2013-04-30
HRP20040367B1 (en) 2012-07-31
AU2002333134B2 (en) 2007-08-02
ES2298431T3 (es) 2008-05-16
NO20042167L (no) 2004-05-25
SI1441701T1 (sl) 2008-08-31
KR101094084B1 (ko) 2011-12-15
EG24380A (en) 2009-04-05
PT1441701E (pt) 2008-04-07
CA2463947C (en) 2009-05-19
KR20040047961A (ko) 2004-06-05
IL161299A0 (en) 2004-09-27
BR0213477A (pt) 2004-11-03
EP1441701B1 (en) 2008-02-13
ATE385781T1 (de) 2008-03-15
CN1575163A (zh) 2005-02-02
PE20030638A1 (es) 2003-07-21
CN100591329C (zh) 2010-02-24
US20030096840A1 (en) 2003-05-22
US20080131516A1 (en) 2008-06-05
EP1441701A1 (en) 2004-08-04
ZA200402584B (en) 2005-06-29

Similar Documents

Publication Publication Date Title
ECSP045082A (es) Formulación granular
SV2004001367A (es) Compuestos y procedimientos antitumorales ref.x-15365
BR0308452A (pt) composições farmacêuticas e métodos de preparação de composição farmacêutica
NO20040125L (no) Enterale formuleringer
SI1818057T1 (sl) Stabilne farmacevtske formulacije montelukast natrija
DE60109207T8 (de) Orale zusammensetzung
DE60218175D1 (de) Stabilisierte orale suspensionsformulierung
PL375874A1 (pl) Wodne kompozycje farmaceutyczne 2,6-diizopropylofenolu
DK1458377T3 (da) Farmaceutiske sammensætninger indeholdende tegaserod
BR0300709A (pt) Sal de perindopril e as composições farmacêuticas contendo o mesmo
DK1608344T3 (da) Orale cladribin-formuleringer
BRPI0415428A (pt) formulações terapêuticas
ATE321760T1 (de) N-aryl-2-oxazolidinone und deren derivate
ITRM20020357A1 (it) Composizione liquida per la somministrazione orale di lorazepam.
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
MA27922A1 (fr) Formulations semi-solides de derives d'azetidine
BRPI0410638A (pt) derivados de azitromicina
HN2002000331A (es) Composiciones farmaceuticas de 5,7,14-triazatetra-ciclo (10.3.1.02,11.04,9)-hexadeca-2(11) 3,5,7,9-pentaeno
HN2002000112A (es) Sal citrato de 5, 8,14 - triazatetraciclo [10.3.1.02.11.04.9] - hexadeca - 2 (11),3,5,7,9 - pentaeno y composiciones farmaceuticas de la misma.
EP1399150A4 (en) VITAMIN C COMPOSITIONS
NO20040454L (no) Stabilisert oral suspensjonformulering.
HN2001000135A (es) Derivados de purina
HN2002000158A (es) Compuestos heterociclicos sustituidos con triamida
HN2001200000A (es) Suspension de ziprasidona
RU2002131660A (ru) Антидот